<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36349400</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Clinical trials on the pharmacological treatment of long COVID: A systematic review.</ArticleTitle><Pagination><StartPage>e28289</StartPage><MedlinePgn>e28289</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e28289</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.28289</ELocationID><Abstract><AbstractText>The postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), also known as post-acute coronavirus disease 19 (COVID-19) or the long COVID syndrome (long COVID) is an emerging public health concern. A substantial proportion of individuals may remain symptomatic months after initial recovery. An updated review of published and ongoing trials focusing on managing long COVID will help identify gaps and address the unmet needs of patients suffering from this potentially debilitating syndrome. A comprehensive literature search was conducted on the international databases and clinical trial registries from inception to 31 July 2022. This review included 6 published trials and 54 trial registration records. There is significant heterogeneity in the characterization of long COVID and ascertainment of primary outcomes. Most of the trials are focused on individual symptoms of long COVID or isolated organ dysfunction, classified according to cardiovascular, respiratory and functional capacity, neurological and psychological, fatigue, and olfactory dysfunction. Most of the interventions are related to the mechanisms causing the individual symptoms. Although the six published trials showed significant improvement in the symptoms or organ dysfunction studied, these initial studies lack internal and external validity limiting the generalizability. This review provides an update of the pharmacological agents that could be used to treat long COVID. Further standardization of the diagnostic criteria, inclusion of participants with concomitant chronic cardiometabolic diseases and standardization of outcomes will be essential in future clinical trials.</AbstractText><CopyrightInformation>&#xa9; 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chee</LastName><ForeName>Ying Jie</ForeName><Initials>YJ</Initials><Identifier Source="ORCID">0000-0002-5068-4960</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology, Tan Tock Seng Hospital, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Bingwen Eugene</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Department of Haematology, Tan Tock Seng Hospital, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Barnaby Edward</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>National Centre for Infectious Diseases, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalan</LastName><ForeName>Rinkoo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Tan Tock Seng Hospital, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lye</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>National Centre for Infectious Diseases, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">pharmacological treatments</Keyword><Keyword MajorTopicYN="N">post-acute sequelae</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>9</Day><Hour>3</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36349400</ArticleId><ArticleId IdType="pmc">PMC9878018</ArticleId><ArticleId IdType="doi">10.1002/jmv.28289</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Institute for Health Metrics and Evaluation
.&#xa0;2022. COVID&#x2010;19 policy briefings.&#xa0;Accessed September 28,&#xa0;2022.&#xa0;https://www.healthdata.org/covid/updates
</Citation></Reference><Reference><Citation>Araf Y, Akter F, Tang Y, et al. Omicron variant of SARS&#x2010;CoV&#x2010;2: genomics, transmissibility, and responses to current COVID&#x2010;19 vaccines. J Med Virol. 2022;94(5):1825&#x2010;1832. 10.1002/jmv.27588</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27588</ArticleId><ArticleId IdType="pmc">PMC9015557</ArticleId><ArticleId IdType="pubmed">35023191</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamble P, Daulatabad V, Patil R, John NA, John J. Omicron variant in COVID&#x2010;19 current pandemic: a reason for apprehension. Horm Mol Biol Clin Investig. Published online September 5, 2022. 10.1515/hmbci-2022-0010</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hmbci-2022-0010</ArticleId><ArticleId IdType="pubmed">36064193</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilazi M, Duffy EY, Thakkar A, Michos ED. COVID and cardiovascular disease: what we know in 2021. Curr Atheroscler Rep. 2021;23(7):37. 10.1007/s11883-021-00935-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11883-021-00935-2</ArticleId><ArticleId IdType="pmc">PMC8117457</ArticleId><ArticleId IdType="pubmed">33983522</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post&#x2010;acute sequelae of COVID&#x2010;19 (PASC): an overview of biological factors that&#xa0;may contribute to persistent symptoms. Front Microbiol. 2021;12:698169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long&#x2010;haul COVID. Nature Immunol. 2022;23(2):194&#x2010;202. 10.1038/s41590-021-01104-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nature Med. 2021;27(4):601&#x2010;615. 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post&#x2010;COVID&#x2010;19 Condition . A clinical case definition of post&#x2010;COVID&#x2010;19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2010;e107. 10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Taylor S. NICE guideline on long covid. BMJ. 2020;371:m4938. 10.1136/bmj.m4938</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4938</ArticleId><ArticleId IdType="pubmed">33361141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nittas V, Gao M, West EA, et al. Long COVID through a public health lens: an umbrella review. Public Health Rev. 2022;43:1604501. 10.3389/phrs.2022.1604501</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/phrs.2022.1604501</ArticleId><ArticleId IdType="pmc">PMC8963488</ArticleId><ArticleId IdType="pubmed">35359614</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9):e005427. 10.1136/bmjgh-2021-005427</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Bierle DM, Aakre CA, Grach SL, et al. Central sensitization phenotypes in post acute sequelae of SARS&#x2010;CoV&#x2010;2 infection (PASC): defining the post COVID syndrome. J Prim Care Community Health. 2021;12:215013272110308. 10.1177/21501327211030826</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/21501327211030826</ArticleId><ArticleId IdType="pmc">PMC8267019</ArticleId><ArticleId IdType="pubmed">34231404</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran AV. Long COVID&#x2010;19: challenges in the diagnosis and proposed diagnostic criteria. Diabetes Metab Syndr: Clin Res Rev. 2021;15(1):145&#x2010;146. 10.1016/j.dsx.2020.12.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.12.025</ArticleId><ArticleId IdType="pmc">PMC7737559</ArticleId><ArticleId IdType="pubmed">33341598</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty SE, Guo Y, Heath K, et al. Risk of clinical sequelae after the acute phase of SARS&#x2010;CoV&#x2010;2 infection: retrospective cohort study. BMJ. 2021;373:n1098. 10.1136/bmj.n1098</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1098</ArticleId><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS&#x2010;CoV&#x2010;2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251&#x2010;2252. 10.1001/jama.2020.22717</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22717</ArticleId><ArticleId IdType="pubmed">33206133</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson KB, Rao M, Bonilla H, et al. Patients with uncomplicated coronavirus disease 2019 (COVID&#x2010;19) have&#xa0;long&#x2010;term persistent symptoms and functional impairment similar to patients with severe COVID&#x2010;19: a&#xa0;cautionary tale during a global pandemic. Clin Infect Dis. 2021;73(3):e826&#x2010;e829. 10.1093/cid/ciab103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab103</ArticleId><ArticleId IdType="pmc">PMC7929039</ArticleId><ArticleId IdType="pubmed">33624010</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro&#x2010;Almagro F, et al. SARS&#x2010;CoV&#x2010;2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697&#x2010;707. 10.1038/s41586-022-04569-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al&#x2010;Aly Z. Long&#x2010;term cardiovascular outcomes of COVID&#x2010;19. Nature Med. 2022;28(3):583&#x2010;590. 10.1038/s41591-022-01689-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Al&#x2010;Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10(5):311&#x2010;321. 10.1016/S2213-8587(22)00044-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00044-4</ArticleId><ArticleId IdType="pmc">PMC8937253</ArticleId><ArticleId IdType="pubmed">35325624</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, et al. Post&#x2010;discharge persistent symptoms and health&#x2010;related quality of life after hospitalization for COVID&#x2010;19. J Infect. 2020;81(6):e4&#x2010;e6. 10.1016/j.jinf.2020.08.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Leber A, Jawad MY, et al. Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research. Infect Dis. 2022;54(7):467&#x2010;477. 10.1080/23744235.2022.2043560</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2022.2043560</ArticleId><ArticleId IdType="pmc">PMC8935463</ArticleId><ArticleId IdType="pubmed">35282780</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson E, Hemenway AN. A scoping review of pharmacological management of postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection in 2021. Am J Ther. 2022;29(3):e305&#x2010;e321. 10.1097/MJT.0000000000001486</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MJT.0000000000001486</ArticleId><ArticleId IdType="pubmed">35383586</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. 10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S, Ibnhadjamor H, Jdidi J, et al. Sulodexide significantly improves endothelial dysfunction and alleviates chest pain and palpitations in patients with&#xa0;long&#x2010;COVID&#x2010;19: insights from TUN&#x2010;EndCOV study. Front Cardiovasc Med. 2022;9:866113. 10.3389/fcvm.2022.866113</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.866113</ArticleId><ArticleId IdType="pmc">PMC9133483</ArticleId><ArticleId IdType="pubmed">35647070</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadhav K, Jariwala P. &#x2018;Ivabradin&#x2019; versus &#x2018;carvedilol&#x2019; in the management of Post&#x2010;COVID&#x2010;19 palpitation with sinus tachycardia. Indian Heart J. 2020;72:S33. 10.1016/j.ihj.2020.11.092</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ihj.2020.11.092</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhooria S, Chaudhary S, Sehgal IS, et al. High&#x2010;dose versus low&#x2010;dose prednisolone in symptomatic patients with post&#x2010;COVID&#x2010;19 diffuse parenchymal lung abnormalities: an open&#x2010;label, randomised trial (the COLDSTER trial). Eur Respir J. 2022;59(2):2102930. 10.1183/13993003.02930-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02930-2021</ArticleId><ArticleId IdType="pmc">PMC8850687</ArticleId><ArticleId IdType="pubmed">34887325</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A, D'Ascanio L, Vaira LA, et al. Ultramicronized palmitoylethanolamide and luteolin supplement combined with olfactory training to treat Post&#x2010;COVID&#x2010;19 olfactory impairment:&#xa0;a&#xa0;multi&#x2010;center double&#x2010;blinded randomized placebo&#x2010;controlled clinical trial. Curr Neuropharmacol. 2022;20:2001&#x2010;2012. 10.2174/1570159X20666220420113513</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X20666220420113513</ArticleId><ArticleId IdType="pmc">PMC9886808</ArticleId><ArticleId IdType="pubmed">35450527</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabico S, Enani MA, Sheshah E, et al. Effects of a 2&#x2010;week 5000 IU versus 1000 IU vitamin D3 supplementation on recovery of symptoms in patients with mild to moderate Covid&#x2010;19: a&#xa0;randomized clinical trial. Nutrients. 2021;13(7):2170. 10.3390/nu13072170</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13072170</ArticleId><ArticleId IdType="pmc">PMC8308273</ArticleId><ArticleId IdType="pubmed">34202578</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathi A, Jadhav SB, Shah N. A randomized controlled trial of the efficacy of systemic enzymes and probiotics in the resolution of post&#x2010;COVID fatigue. Medicines. 2021;8(9):47. 10.3390/medicines8090047</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines8090047</ArticleId><ArticleId IdType="pmc">PMC8472462</ArticleId><ArticleId IdType="pubmed">34564089</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabaan AA, Al&#x2010;Ahmed SH, Muhammad J, et al. (2021). role of inflammatory cytokines in COVID&#x2010;19 patients:&#xa0;a&#xa0;review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines. 2021;9(5):436. 10.3390/vaccines9050436</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9050436</ArticleId><ArticleId IdType="pmc">PMC8145892</ArticleId><ArticleId IdType="pubmed">33946736</ArticleId></ArticleIdList></Reference><Reference><Citation>Maamar M, Artime A, Pariente E, et al. Post&#x2010;COVID&#x2010;19 syndrome, low&#x2010;grade inflammation and inflammatory markers: a cross&#x2010;sectional study. Curr Med Res Opin. 2022;38(6):901&#x2010;909. 10.1080/03007995.2022.2042991</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2022.2042991</ArticleId><ArticleId IdType="pmc">PMC8935459</ArticleId><ArticleId IdType="pubmed">35166141</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollenberg R, Tepasse PR, Ochs K, et al. Indications of persistent glycocalyx damage in convalescent COVID&#x2010;19 patients:&#xa0;a&#xa0;prospective multicenter study and hypothesis. Viruses. 2021;13(11):2324. 10.3390/v13112324</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13112324</ArticleId><ArticleId IdType="pmc">PMC8619155</ArticleId><ArticleId IdType="pubmed">34835130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori Y, Hattori K, Machida T, Matsuda N. Vascular endotheliitis associated with infections: its pathogenetic role and therapeutic implication. Biochem Pharmacol. 2022;197:114909. 10.1016/j.bcp.2022.114909</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2022.114909</ArticleId><ArticleId IdType="pmc">PMC8743392</ArticleId><ArticleId IdType="pubmed">35021044</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing C, Gluckman TJ, Bhave NM, et al. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID&#x2010;19 in adults: myocarditis and other myocardial involvement,&#xa0;post&#x2010;acute sequelae of SARS&#x2010;CoV&#x2010;2 infection, and return to play:&#xa0;a&#xa0;report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;79(17):1717&#x2010;1756. 10.1016/j.jacc.2022.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.02.003</ArticleId><ArticleId IdType="pmc">PMC8926109</ArticleId><ArticleId IdType="pubmed">35307156</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008;10:550&#x2010;555. 10.1016/j.ejheart.2008.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejheart.2008.04.005</ArticleId><ArticleId IdType="pubmed">18486549</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Fogarty H, Dyer A, et al. Prolonged elevation of D&#x2010;dimer levels in convalescent COVID&#x2010;19 patients is independent of the acute phase response. J Thromb Haemostasis. 2021;19(4):1064&#x2010;1070. 10.1111/jth.15267</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15267</ArticleId><ArticleId IdType="pmc">PMC8013297</ArticleId><ArticleId IdType="pubmed">33587810</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan BE, Wong SW, Sum CLL, et al. Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: assessing the long&#x2010;term outcomes in COVID&#x2010;19 patients. Am J Hematol. 2022;97(7):915&#x2010;923. 10.1002/ajh.26575</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26575</ArticleId><ArticleId IdType="pmc">PMC9073976</ArticleId><ArticleId IdType="pubmed">35477923</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook&#x2010;Mills JM, Deem TL. Active participation of endothelial cells in inflammation. J Leukoc Biol. 2005;77(4):487&#x2010;495. 10.1189/jlb.0904554</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0904554</ArticleId><ArticleId IdType="pmc">PMC2710032</ArticleId><ArticleId IdType="pubmed">15629883</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RC. COVID&#x2010;19 update: Covid&#x2010;19&#x2010;associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54&#x2010;67. 10.1007/s11239-020-02134-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02134-3</ArticleId><ArticleId IdType="pmc">PMC7225095</ArticleId><ArticleId IdType="pubmed">32415579</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos AC, Anderson FA, Jr. , FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706&#x2010;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">21436241</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfrum S, Jensen KS, Liao JK. Endothelium&#x2010;dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003;23(5):729&#x2010;736. 10.1161/01.ATV.0000063385.12476.A7</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000063385.12476.A7</ArticleId><ArticleId IdType="pubmed">12615672</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchesi S, Lupattelli G, Siepi D, et al. Short&#x2010;term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol. 2000;36(5):617&#x2010;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">11065222</ArticleId></ArticleIdList></Reference><Reference><Citation>Darwesh AM, Bassiouni W, Sosnowski DK, Seubert JM. Can N&#x2010;3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID&#x2010;19&#x2010;associated cardiovascular complications? Pharmacol Ther. 2021;219:107703. 10.1016/j.pharmthera.2020.107703</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2020.107703</ArticleId><ArticleId IdType="pmc">PMC7534795</ArticleId><ArticleId IdType="pubmed">33031856</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B, Larson C, Hammond TC, et al. A review of persistent&#xa0;post&#x2010;COVID syndrome (PPCS). Clin Rev Allergy Immunol. Published online February 20, 2021;. 10.1007/s12016-021-08848-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08848-3</ArticleId><ArticleId IdType="pmc">PMC7896544</ArticleId><ArticleId IdType="pubmed">33609255</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early&#x2010;phase 2019 novel coronavirus (COVID&#x2010;19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15(5):700&#x2010;704. 10.1016/j.jtho.2020.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2020.02.010</ArticleId><ArticleId IdType="pmc">PMC7128866</ArticleId><ArticleId IdType="pubmed">32114094</ArticleId></ArticleIdList></Reference><Reference><Citation>Cueto&#x2010;Robledo G, Porres&#x2010;Aguilar M, Puebla&#x2010;Aldama D, et al. Severe pulmonary hypertension: an important sequel after severe&#xa0;post&#x2010;acute COVID&#x2010;19 pneumonia. Curr Probl Cardiol. 2022;47(3):101004. 10.1016/j.cpcardiol.2021.101004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2021.101004</ArticleId><ArticleId IdType="pmc">PMC8482545</ArticleId><ArticleId IdType="pubmed">34601005</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID&#x2010;19; metcovid):&#xa0;a&#xa0;randomized, double&#x2010;blind, phase IIb, placebo&#x2010;controlled trial. Clin Infect Dis. 2021;72(9):e373&#x2010;e381. 10.1093/cid/ciaa1177</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1177</ArticleId><ArticleId IdType="pmc">PMC7454320</ArticleId><ArticleId IdType="pubmed">32785710</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID&#x2010;19): a&#xa0;prospective cohort study. Clin Infect Dis. 2022;74(7):1191&#x2010;1198. 10.1093/cid/ciab611</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero&#x2010;S&#xe1;nchez CM, D&#xed;az&#x2010;Maroto I, Fern&#xe1;ndez&#x2010;D&#xed;az E, et al. Neurologic manifestations in hospitalized patients with COVID&#x2010;19: the ALBACOVID registry. Neurology. 2020;95(8):e1060&#x2010;e1070. 10.1212/WNL.0000000000009937</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009937</ArticleId><ArticleId IdType="pmc">PMC7668545</ArticleId><ArticleId IdType="pubmed">32482845</ArticleId></ArticleIdList></Reference><Reference><Citation>Septyaningtrias DE, Susilowati R. Neurological involvement of COVID&#x2010;19: from neuroinvasion and neuroimmune crosstalk to long&#x2010;term consequences. Rev Neurosci. 2021;32(4):427&#x2010;442. 10.1515/revneuro-2020-0092</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2020-0092</ArticleId><ArticleId IdType="pubmed">33550780</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS&#x2010;CoV&#x2010;2 invasion as a port of central nervous system entry in individuals with COVID&#x2010;19. Nature Neurosci. 2021;24(2):168&#x2010;175. 10.1038/s41593-020-00758-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00758-5</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollbracht C, Kraft K. Oxidative stress and hyper&#x2010;inflammation as major drivers of severe COVID&#x2010;19 and long COVID: implications for the benefit of high&#x2010;dose intravenous vitamin C. Front Pharmacol. 2022;13:899198. 10.3389/fphar.2022.899198</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.899198</ArticleId><ArticleId IdType="pmc">PMC9100929</ArticleId><ArticleId IdType="pubmed">35571085</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild&#x2010;to&#x2010;moderate SARS&#x2010;CoV&#x2010;2 infection. Nature Immunol. 2022;23(2):210&#x2010;216. 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr A, Maggini S. Vitamin C and immune function. Nutrients. 2017;9(11):1211. 10.3390/nu9111211</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu9111211</ArticleId><ArticleId IdType="pmc">PMC5707683</ArticleId><ArticleId IdType="pubmed">29099763</ArticleId></ArticleIdList></Reference><Reference><Citation>Holford P, Carr AC, Jovic TH, et al. Vitamin C&#x2010;An adjunctive therapy for respiratory infection, sepsis and COVID&#x2010;19. Nutrients. 2020;12(12):3760. 10.3390/nu12123760</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12123760</ArticleId><ArticleId IdType="pmc">PMC7762433</ArticleId><ArticleId IdType="pubmed">33297491</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Rao X, Li Y, et al. Pilot trial of high&#x2010;dose vitamin C in critically ill COVID&#x2010;19 patients. Ann Intensive Care. 2021;11(1):5. 10.1186/s13613-020-00792-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-020-00792-3</ArticleId><ArticleId IdType="pmc">PMC7794643</ArticleId><ArticleId IdType="pubmed">33420963</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollbracht C, Kraft K. Feasibility of vitamin C in the treatment of post viral fatigue with focus on long COVID, based on a systematic review of IV vitamin C on fatigue. Nutrients. 2021;13(4):1154. 10.3390/nu13041154</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13041154</ArticleId><ArticleId IdType="pmc">PMC8066596</ArticleId><ArticleId IdType="pubmed">33807280</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Meza CA, Clarke H, Kim JS, Hickner RC. Vitamin D and endothelial function. Nutrients. 2020;12(2):575. 10.3390/nu12020575</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12020575</ArticleId><ArticleId IdType="pmc">PMC7071424</ArticleId><ArticleId IdType="pubmed">32098418</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, McCluskey P, et al. Investigating the relationship between vitamin D and persistent symptoms following SARS&#x2010;CoV&#x2010;2 infection. Nutrients. 2021;13(7):2430. 10.3390/nu13072430</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13072430</ArticleId><ArticleId IdType="pmc">PMC8308626</ArticleId><ArticleId IdType="pubmed">34371940</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNicolantonio JJ, McCarty MF, Barroso&#x2010;Aranda J, Assanga S, Lujan LML, O'Keefe JH. A nutraceutical strategy for downregulating TGF&#x3b2; signalling: prospects for prevention of fibrotic disorders, including post&#x2010;COVID&#x2010;19 pulmonary fibrosis. Open Heart. 2021;8(1):e001663. 10.1136/openhrt-2021-001663</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2021-001663</ArticleId><ArticleId IdType="pmc">PMC8061562</ArticleId><ArticleId IdType="pubmed">33879509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q, Wang B, Li Y, et al. Taurine supplementation lowers blood pressure and improves vascular function in prehypertension: randomized, double&#x2010;blind, placebo&#x2010;controlled study. Hypertension. 2016;67(3):541&#x2010;549. 10.1161/HYPERTENSIONAHA.115.06624</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.115.06624</ArticleId><ArticleId IdType="pubmed">26781281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerman A, Burnett JC, Jr. , Higano ST, McKinley LJ, Holmes DR. Long&#x2010;terml&#x2010;arginine supplementation improves small&#x2010;vessel coronary endothelial function in humans. Circulation. 1998;97(21):2123&#x2010;2128. 10.1161/01.cir.97.21.2123</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.97.21.2123</ArticleId><ArticleId IdType="pubmed">9626172</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Mak JWY, Su Q, et al. Gut microbiota dynamics in a prospective cohort of patients with post&#x2010;acute COVID&#x2010;19 syndrome. Gut. 2022;71(3):544&#x2010;552. 10.1136/gutjnl-2021-325989</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilpert K, Mikut R. Is there a connection between gut microbiome dysbiosis occurring in COVID&#x2010;19 patients and post&#x2010;COVID&#x2010;19 symptoms? Front Microbiol. 2021;12:732838. 10.3389/fmicb.2021.732838</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.732838</ArticleId><ArticleId IdType="pmc">PMC8485028</ArticleId><ArticleId IdType="pubmed">34603261</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Zhang L, Wang Y, et al. Alterations in microbiota of patients with COVID&#x2010;19: potential mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022;7(1):143. 10.1038/s41392-022-00986-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00986-0</ArticleId><ArticleId IdType="pmc">PMC9052735</ArticleId><ArticleId IdType="pubmed">35487886</ArticleId></ArticleIdList></Reference><Reference><Citation>Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020;41(9):653&#x2010;664. 10.1016/j.tips.2020.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2020.06.009</ArticleId><ArticleId IdType="pmc">PMC7751844</ArticleId><ArticleId IdType="pubmed">32709406</ArticleId></ArticleIdList></Reference><Reference><Citation>Loke XY, Imran SAM, Tye GJ, Wan Kamarul Zaman WS, Nordin F. Immunomodulation and regenerative capacity of MSCs for Long&#x2010;COVID. Int J Mol Sci. 2021;22(22):12421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8625432</ArticleId><ArticleId IdType="pubmed">34830303</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu TY, Lee MK. Autonomic dysfunction, diabetes and metabolic syndrome. J Diabetes Investig. 2021;12(12):2108&#x2010;2111. 10.1111/jdi.13691</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.13691</ArticleId><ArticleId IdType="pmc">PMC8668070</ArticleId><ArticleId IdType="pubmed">34622579</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>